PCN17 Indirect Comparison of the Efficacy of Erlotinib Versus Pemetrexed Plus Cisplatin as First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1211
https://www.valueinhealthjournal.com/article/S1098-3015(12)02924-5/fulltext
Title :
PCN17 Indirect Comparison of the Efficacy of Erlotinib Versus Pemetrexed Plus Cisplatin as First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02924-5&doi=10.1016/j.jval.2012.08.1211
First page :
A411
Section Title :
Cancer
Open access? :
No
Section Order :
710